OTCMKTS:BRRGF - BerGenBio ASA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.50
▼ -0.02 (-0.57%)

This chart shows the closing price for BRRGF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BerGenBio ASA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BRRGF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BRRGF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for BerGenBio ASA in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.50.

This chart shows the closing price for BRRGF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in BerGenBio ASA.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/8/2021HC WainwrightReiterated RatingBuy
3/11/2020HC WainwrightReiterated RatingBuy ➝ Average
12/11/2019HC WainwrightReiterated RatingBuy
(Data available from 9/27/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
BerGenBio ASA logo
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. The company's Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase I clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is headquartered in Bergen, Norway.
Read More

Today's Range

Now: $3.50
Low: $3.50
High: $3.52

50 Day Range

MA: $3.50
Low: $3.50
High: $3.50

52 Week Range

Now: $3.50
Low: $2.95
High: $4.20

Volume

400 shs

Average Volume

1,217 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of BerGenBio ASA?

The following Wall Street analysts have issued stock ratings on BerGenBio ASA in the last year: HC Wainwright.
View the latest analyst ratings for BRRGF.

What is the current price target for BerGenBio ASA?

0 Wall Street analysts have set twelve-month price targets for BerGenBio ASA in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for BerGenBio ASA in the next year.
View the latest price targets for BRRGF.

What is the current consensus analyst rating for BerGenBio ASA?

BerGenBio ASA currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BRRGF will outperform the market and that investors should add to their positions of BerGenBio ASA.
View the latest ratings for BRRGF.

What other companies compete with BerGenBio ASA?

How do I contact BerGenBio ASA's investor relations team?

BerGenBio ASA's physical mailing address is Jonas Lies Vei 91, Bergen, Hordaland 5009. The company's listed phone number is 47 53 50 15 64. The official website for BerGenBio ASA is www.bergenbio.com.